Seoul, South Korea, 23 August 2023 – MGI, a global leader in life science technology, and NGeneBio, a company specialising in next-generation sequencing (NGS)-based diagnostics, have signed a memorandum of understanding (MOU) to expand global access to NGeneBio’s cancer testing products. This strategic partnership will integrate NGeneBio’s advanced diagnostic assays with MGI’s high-throughput sequencing technology, accelerating the development and application of cutting-edge sequencing products in precision medicine and improving patient access to accurate diagnostics and personalised treatment options.
Under the MOU, NGeneBio’s NGS cancer precision diagnostic products will be applied on MGI’s DNBSEQ-G99 sequencing platform, providing healthcare professionals with a powerful and reliable tool for precision diagnosis and personalised treatment. The two companies will also collaborate on regional clinical trials and initiatives across the APAC region, leveraging MGI’s extensive network of partners and distributors to enhance the accessibility and commercialisation of cost-effective, state-of-the-art NGS solutions.
“MGI is proud to collaborate with NGeneBio to develop and commercialise an integrated precision diagnostic platform that enhances the accuracy and efficiency of diagnostic tests,” said Dr Roy Tan, General Manager of MGI Asia Pacific. “By partnering with NGeneBio, MGI aims to lead the way in providing healthcare professionals with innovative solutions that improve patient care and health outcomes globally.”
The field of precision medicine is growing rapidly, with NGS technology playing a central role in enabling personalised diagnosis and treatment. MGI’s DNBSEQ-G99 sequencer is recognised for its speed and high accuracy, making it an ideal platform for NGS-based precision diagnostics. NGeneBio’s expertise in NGS-based precision diagnostic assays complements MGI’s sequencing platforms, creating a powerful synergy to advance precision medicine.
“We are extremely excited to partner with MGI to develop and deliver cutting-edge diagnostic products that have the potential to transform healthcare and improve patient outcomes,” said Choi Dae-chul, CEO of NGeneBio. “By combining NGeneBio’s NGS-based cancer panels and clinical analysis software with MGI’s DNBSEQ™ technology, we can offer a comprehensive solution for healthcare providers worldwide.”
The partnership between MGI and NGeneBio represents a significant step towards advancing precision medicine in the region. By combining their expertise and technologies, the companies aim to make NGS-based precision diagnostics more accessible, cost-effective, and impactful. Through joint efforts in clinical trials, commercialisation, and business development, MGI and NGeneBio will contribute to the growth of precision medicine and improve patient outcomes across Asia and beyond.
About NGeneBio
NGeneBio Co., Ltd., headquartered in Seoul, Korea, develops innovative healthcare technologies by combining biotechnology, healthcare, and information technology. NGeneBio began as an in-house venture of KT in 2010, Korea’s first high-capacity genome platform, and was established as NGeneBio in October 2015.
NGeneBio provides certified NGS panels and analysis software to medical institutions and leverages a precision diagnostics platform for early and companion diagnostics and digital health applications. NGeneBio is recognised as a global leader in medical precision diagnostics, having developed BRCAaccuTest™, the first breast/ovarian cancer diagnostic test approved by the Korean FDA and the first in Asia to receive in vitro diagnostic approval from the European Union.
